| Pathology chief backs latest autopsy report | | Posted Friday, December 01, 2006 1:01:03 PM by Blog57 Team | | The Dean of the Faculty of Pathology, Dr Gerard Boran, has welcomed the publication of the report by the Department of Health Working Group on Post-mortem Practice, which was chaired by UCC law lecturer Dr Deirdre Madden. The Faculty welcomes the report and congratulates Dr Madden and her Committee for an excellent job. The report is fair and makes broadly sensible recommendations which should be a good basis for future legislation, Dr Boran told IMN. Speaking beforehand to IMN, Dr Madden has stressed that she does not regard the report as her report, but a report by the people affected by the issues it studied, pointing out that a range of interested parties were members of the Working Group. Dr Madden said it was very important these groups voices were integrated into the report.... | |
| |
| | | AMBFF: Study Shows Ambrilia's PSP94 Immunoassay to Have Prognostic Value in Prostate Cancer Management | | Posted Friday, November 03, 2006 3:13:12 AM by Blog57 Team | | Ambrilia Biopharma Inc. (AMBFF) announced that the findings of an extensive study conducted in collaboration with Dr. Dharam Ramnani, Laboratory Director at the Virginia Urology Pathology Laboratory, Richmond, Virginia, with its PSP94 (Prostate Secretory Protein of 94 amino acids) immunoassay for the diagnosis and prognosis of prostate cancer, were published in the October 15th issue of Clinical Cancer Research (Vol. 12, pp. 6018 - 6022). Results of the study show that in prostate cancer patients who had undergone surgery (radical prostatectomy), pre-surgery PSP94 (bound/free ratio) as well as PSPBP (PSP binding protein) were independent predictive markers of a potential recurrence of the cancer in comparison with initial total PSA (Prostate Specific Antigen), Gleason score or surgical margin status.... | |
| |
| | | Australia's Sonic flags slower EPS growth; shares fall | | Posted Wednesday, August 23, 2006 10:57:10 PM by Blog57 Team | | SYDNEY, Aug 22 (Reuters) - Australia's top pathology group, Sonic Healthcare Ltd. , flagged slower earnings growth this year, missing analysts' forecasts and knocking its shares down as much as 7 percent to their lowest in more than a year. Sonic, which also fell short of market estimates with a 27 percent rise in annual profit, said earnings per share would increase 10 percent in fiscal 2007 -- half the EPS growth it achieved in the year to June 30. The 64.5 cents per share earnings guidance was 7.6 percent below the average forecast of five analysts for 69.8 cents this year, according to Reuters Estimates. Sonic shares fell to a 15-month low of A$11.12, while rivals Symbion Health Ltd. and DCA Group Ltd. also weakened. "People knew there was some pain to come. There hasn't been any enthusiasm built into the share price for the last nine months, but now finally we've got the numbers we can move on a little," said Andrew Goodsall, analyst at UBS.... | |
| |
| | | Washington U. names Virgin head of pathology, immunology | | Posted Saturday, July 22, 2006 9:01:23 AM by Blog57 Team | | Dr. Herbert "Skip" Virgin was named head of the department of pathology and immunology at Washington University School of Medicine in St. Louis. Virgin joined the department in 1990 as an instructor and became a professor in 2002. Succeeding Dr. Emil Unanue, who served as head of the department for 21 years, Virgin becomes Edward Mallinckrodt Professor of Pathology and Immunology. .... | |
| |
| |
|
|
